{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-MJCRWDDF/bfc5812f-f4f8-4b0a-a359-64e45d04c298/PDF","dcterms:extent":"101 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-MJCRWDDF/0ffa8aca-1fc5-4ad3-8b05-b801f3b13b80/TEXT","dcterms:extent":"21 KB"}],"edm:TimeSpan":{"@rdf:about":"1997-2025","edm:begin":{"@xml:lang":"en","#text":"1997"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-MJCRWDDF","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-S2P9OQWZ"},{"@xml:lang":"sl","#text":"Onkologija (Ljubljana)"}],"dcterms:issued":"2018","dc:creator":"Mencinger, Marina","dc:format":[{"@xml:lang":"sl","#text":"številka:1"},{"@xml:lang":"sl","#text":"letnik:22"},{"@xml:lang":"sl","#text":"str. 24-27"}],"dc:identifier":["ISSN:1408-1741","COBISSID_HOST:2990971","URN:URN:NBN:SI:doc-MJCRWDDF"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Onkološki inštitut Ljubljana"},"dc:subject":[{"@xml:lang":"en","#text":"side effects"},{"@xml:lang":"sl","#text":"stranski učinki"},{"@xml:lang":"sl","#text":"tarčna zdravila"},{"@xml:lang":"en","#text":"targeted drugs"},{"@xml:lang":"en","#text":"tyrosine kinase inhibitors"},{"@xml:lang":"sl","#text":"zaviralci tirozinskih kinaz"}],"dcterms:temporal":{"@rdf:resource":"1997-2025"},"dc:title":{"@xml:lang":"sl","#text":"Stranski učinki ob zdravljenju rakavih bolezni z zaviralci tirozinskih kinaz| Side effects of tyrosine kinase inhibitors in cancer treatment|"},"dc:description":{"@xml:lang":"sl","#text":"Zaviralci tirozin-kinaz so multitarčna zdravila, ki prek zaviranja različnih celičnih procesov učinkujejo pri več vrstah rakavih boleznih. Čeprav so stranski učinki ob zaviralcih tirozinskih kinaz v splošnem prenosljivi, pa so lahko tudi resni in povzročajo nemalo preglavic bolnikom, ki prejemajo zdravila dolgotrajno. Pogosto je potrebno zmanjšanje odmerkov ali prehodna ukinitev, redkeje pa se odločimo za trajno prekinitev zdravljenja. Značilni so kožna toksičnost, kardiovaskularni zapleti, težave gastrointestinalnega trakta - predvsem diareja, nepravilno delovanje ščitnice in utrujenost ob zdravljenju rakave bolezni"},"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-MJCRWDDF","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-MJCRWDDF"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-MJCRWDDF/bfc5812f-f4f8-4b0a-a359-64e45d04c298/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Onkološki inštitut Ljubljana"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-MJCRWDDF/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-MJCRWDDF"}}}}